Savara (NASDAQ:SVRA) released its quarterly earnings data on Thursday. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14, Fidelity Earnings reports.
Shares of NASDAQ SVRA traded down $0.07 during mid-day trading on Friday, reaching $0.84. The company’s stock had a trading volume of 581,000 shares, compared to its average volume of 394,757. The firm has a market capitalization of $40.28 million, a PE ratio of -0.65 and a beta of 0.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 12.61 and a quick ratio of 12.61. The stock has a fifty day moving average of $1.34 and a two-hundred day moving average of $4.38. Savara has a 52 week low of $0.82 and a 52 week high of $11.96.
A number of equities analysts have recently weighed in on the company. LADENBURG THALM/SH SH reaffirmed a “hold” rating and issued a $1.00 price objective on shares of Savara in a research note on Thursday, October 3rd. ValuEngine raised Savara from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Evercore ISI set a $17.00 price objective on Savara and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Zacks Investment Research raised Savara from a “sell” rating to a “hold” rating in a research note on Friday. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $9.09.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Featured Story: Hedge Funds Explained
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.